drugset / Trial / NCT01497561

Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes

NCT01497561

Phase 1 Completed 15 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamics and pharmacokinetics of single doses of insulin detemir and insulin NPH in subjects with type 2 diabetes.

Timeline

Start
2003-03
Primary completion
2003-06
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator insulin NPH Protein / enzyme biologic Subcutaneous
Subject insulin detemir Protein / enzyme biologic Subcutaneous